Buchanan R B, Blamey R W, Durrant K R, Howell A, Paterson A G, Preece P E, Smith D C, Williams C J, Wilson R G
J Clin Oncol. 1986 Sep;4(9):1326-30. doi: 10.1200/JCO.1986.4.9.1326.
We randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy. Of 54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectomy. The median duration of response for tamoxifen (20 months) was longer than that for surgical oophorectomy (7 months), but this did not achieve statistical significance (P = .056). Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy (P = .18). Toxicity was greater in those undergoing oophorectomy, though both treatments were well tolerated. In those premenopausal women for whom hormonal therapy is indicated, tamoxifen is a suitable alternative to surgical oophorectomy.
我们将122名绝经前女性随机分为两组，一组接受他莫昔芬治疗，另一组接受手术去势。在接受他莫昔芬治疗的54名可评估女性中，24%有客观反应，而在接受手术去势的53名女性中这一比例为21%。他莫昔芬组的中位反应持续时间（20个月）长于手术去势组（7个月），但未达到统计学显著性（P = 0.056）。接受他莫昔芬治疗的58例患者的总体中位生存期为15个月，接受去势手术的53例患者为25个月（P = 0.18）。手术去势组的毒性更大，不过两种治疗的耐受性都良好。对于那些适合激素治疗的绝经前女性，他莫昔芬是手术去势的合适替代方案。
